Evaluation of TTP399 in Patients With Type 1 Diabetes
Public ClinicalTrials.gov record NCT03335371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
Study identification
- NCT ID
- NCT03335371
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2017 (Actual)
- Primary completion
- Dec 20, 2019 (Actual)
- Completion
- Jan 6, 2020 (Actual)
- Last update posted
- Jul 3, 2023
2017 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Westside Center for Diabetes | Beverly Hills | California | 90211 | — |
| AMCR Institute | Escondido | California | 92025 | — |
| University of Colorado Barbara Davis Center | Aurora | Colorado | 80045 | — |
| Atlanta Diabetes Associate | Atlanta | Georgia | 30318 | — |
| Rocky Mountain Diabetes Center | Idaho Falls | Idaho | 83404 | — |
| Iowa Diabetes Research | West Des Moines | Iowa | 50265 | — |
| Mountain Diabetes and Endocrine Center | Asheville | North Carolina | 28803 | — |
| UNC Diabetes Care Center | Chapel Hill | North Carolina | 27517 | — |
| Duke University Diabetes Research Clinic | Durham | North Carolina | 27710 | — |
| Diabetes & Endocrinology Consultants | Morehead City | North Carolina | 28557 | — |
| PMG Research of Wilmington | Wilmington | North Carolina | 28401 | — |
| Wake Forest | Winston-Salem | North Carolina | 27104 | — |
| Intend Research | Norman | Oklahoma | 73069 | — |
| Dallas Diabetes Research Center | Dallas | Texas | 75230 | — |
| University of Washington Medicine Diabetes Institute | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03335371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 3, 2023 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03335371 live on ClinicalTrials.gov.